Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000950 · ClinicalTrials.gov registry record · NA
Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT00000950 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 50 participants.
The verdict
NCT00000950, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a relationship exists between the level of antituberculosis drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) in the blood and the outcome of HIV-positive patients with tuberculosis. This study also evaluates how these drugs are absorbed and metabolized in the body.
Interventions
- DRUG Rifampin
- DRUG Pyrazinamide
- DRUG Isoniazid
- DRUG Pyridoxine hydrochloride
- DRUG Ethambutol hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000950
The ClinicalTrials.gov registry entry for NCT00000950 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rifampin is the first listed.
NCT00000950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000950 about?
NCT00000950 is a clinical study titled "Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis". The purpose of this study is to determine if a relationship exists between the level of antituberculosis drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) in the blood and the outcome of HIV-positive patients with tuberculosis. This study also evaluates how these drugs are absorbed and metab...
What is the current status of trial NCT00000950?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants.
What interventions are being tested in trial NCT00000950?
The interventions under investigation include: Rifampin (DRUG), Pyrazinamide (DRUG), Isoniazid (DRUG), Pyridoxine hydrochloride (DRUG), Ethambutol hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00000950?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.